Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair
Status:
Recruiting
Trial end date:
2021-09-15
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine if serial intravitreal aflibercept
injections (IAI) improve the single surgery anatomic success rate following surgical repair
of primary, macula involving rhegmatogenous retinal detachment (RRD) deemed at high risk for
proliferative vitreoretinopathy (PVR). Preclinical work has revealed that competitive
inhibition of platelet derived growth factor (PDGF) by vascular endothelial growth factor
(VEGF) potentiates a pathologic, sustained activation of PDGF receptors that is critical to
the progression of experimental PVR. VEGF blockade would mitigate this pathologic activation.
Phase:
Phase 2
Details
Lead Sponsor:
M. Ali Khan, MD
Collaborators:
Eye Associates of New Mexico Southeastern Retina Associates University of California, Los Angeles